Remicade, Humira and Enbrel made up 40% of the immunomodulators market in 2010; report

Tumor necrosis factor (TNF) inhibitors indicated for the treatment of rheumatoid arthritis, psoriasis and inflammatory bowel disease formed the largest share of the market, according to a new report available on companiesandmarkets.com. The top three products: Johnson & Johnson’s Remicade (infliximab), Abbott Labs’ Humira (adalimumab) and Amgen/Pfizer’s Enbrel (etanercept) accounted for 40.1% of the market in 2010.

Novartis' orally-formulated Gilenya (fingolimod) for multiple sclerosis will gain extensive market share reaching sales of $2.3 billion by 2016. However, Teva’s Copaxone (glatiramer acetate) and Biogen Idec’s Avonex (interferon beta 1a) sales will decline strongly to 2016.

GlaxoSmithKline and Human Genome Sciences' Benlysta (belimumab) was the first product to be approved for the treatment of systemic lupus erythematosus in the past 30 years, a key step in the disease treatment. Benlysta will reach sales of $401 million in 2016, the report states.